+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adult-Onset Still Disease - Pipeline Insight, 2021

  • ID: 5237655
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AB2 Bio Ltd.
  • Cerecor
  • Roche
  • Swedish Orphan Biovitrum
  • MORE
This “Adult-Onset Still Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Adult-Onset Still Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Adult-Onset Still Disease Understanding

Adult-Onset Still Disease: Overview

Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis - fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another and the progression of the disorder is difficult to predict. In some individuals, the disorder appears suddenly, disappears almost as quickly and may not return. In other people, adult-onset Still's disease is a chronic, potentially disabling, condition.

Symptoms

Most people with adult Still's disease have a combination of the following signs and symptoms: Fever, Rash, Sore throat, Achy and swollen joints, and Muscle pain.

Diagnosis

Diagnosing AOSD is difficult because there are no specific tests or distinguishing laboratory (histopathologic) findings that differentiate the disorder from similar disorders. A diagnosis of AOSD is usually made based upon thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and the exclusion of other possible disorders (diagnosis of exclusion). A variety of tests may be performed to aid in the diagnosis, including blood tests and x-ray studies that reveal changes in the bones or joints or enlargement of the spleen or liver. An echocardiogram, which uses sound waves to create a picture of the heart, may reveal inflammation of the pericardium or myocardium.

Treatment

Many different therapies have been tried for individuals with adult-onset Still's disease. No one treatment has proven consistently effective in all cases. A variety of different drugs taken alone or in combination may be used to treat affected individuals. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to treat symptoms of inflammation. Fever, joint pain and bone pain have responded to treatment with these drugs. Other painkillers (analgesics) such as Tylenol (acetaminophen) may also be used. In 2021, the U. S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) to treat patients with active Still's disease, including adult onset Still's disease.

Adult-Onset Still Disease Emerging Drugs Chapters

This segment of the Adult-Onset Still Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adult-Onset Still Disease Emerging Drugs

Tadekinig alfa: AB2 Bio Ltd.

Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein (IL-18BP). It is currently under phase 2 of clinical trials for the indication Adult-onset Still's disease.

CERC-007: Cerecor

CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Adult-onset Still's disease (AOSD) and multiple myeloma (MM). IL-18 is a pro-inflammatory cytokine; patients with AOSD and MM shows elevated levels of IL-18. Cerecor seeks to initiate a phase 1b/2a proof-of-concept study of CERC-007 in AOSD and MM patients in 2021.

Tocilizumab (TCZ) - Roche

TCZ is a humanized anti-IL-6R antibody that binds to both soluble and membranebound IL-6 receptors (sIL-6R and mIL-6R), inhibiting sIL-6R and mIL-6R-mediated signaling. TCZ is available for intravenous (IV) infusion and subcutaneous (SC) injections. It is registered for the indication Adult-onset Still's disease.

Anakinra - Swedish Orphan Biovitrum

Anakinra is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). The drug is produced by recombinant DNA technology using an E. coli bacterial expression system. Anakinra is useful for treating rheumatoid arthritis (RA) and some other inflammatory conditions. It is registered for the indication Adult-onset Still's disease.

Adult-Onset Still Disease: Therapeutic Assessment

This segment of the report provides insights about the different Adult-Onset Still Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Adult-Onset Still Disease

There are approx. 10+ key companies which are developing the therapies for Adult-Onset Still Disease. The companies which have their Adult-Onset Still Disease drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, AB2 Bio Ltd. and others.

Phases

This report covers around 30+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Late-stage products (Phase III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Adult-Onset Still Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intravenous
  • Oral
  • Intramuscular
  • Intradermal
  • subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adult-Onset Still Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adult-Onset Still Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult-Onset Still Disease drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Adult-Onset Still Disease R&D. The therapies under development are focused on novel approaches to treat/improve Adult-Onset Still Disease.
Adult-Onset Still Disease Report Insights
  • Adult-Onset Still Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Adult-Onset Still Disease Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Adult-Onset Still Disease drugs?
  • How many Adult-Onset Still Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adult-Onset Still Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adult-Onset Still Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Adult-Onset Still Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • AB2 Bio Ltd.
  • Cerecor
  • Roche
  • Swedish Orphan Biovitrum
Key Products
  • Tadeking alfa
  • CERC-007
  • Tocilizumab
  • Anakinra

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB2 Bio Ltd.
  • Cerecor
  • Roche
  • Swedish Orphan Biovitrum
  • MORE
Introduction

Executive Summary

Adult-Onset Still Disease: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Adult-Onset Still Disease - Analytical Perspective

In-depth Commercial Assessment
  • Adult-Onset Still Disease companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Adult-Onset Still Disease Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Tadekinig: AB2 Bio ltd.
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Adult-Onset Still Disease Key Companies

Adult-Onset Still Disease Key Products

Adult-Onset Still Disease- Unmet Needs

Adult-Onset Still Disease- Market Drivers and Barriers

Adult-Onset Still Disease- Future Perspectives and Conclusion

Adult-Onset Still Disease Analyst Views

Adult-Onset Still Disease Key Companies

Appendix

List of Tables
Table 1 Total Products for Adult-Onset Still Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Adult-Onset Still Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • AB2 Bio Ltd.
  • Cerecor
  • Roche
  • Swedish Orphan Biovitrum
Note: Product cover images may vary from those shown
Adroll
adroll